Zymeworks : 2025 ZYME Corporate Presentation July final
ZYME
Published on 07/08/2025 at 05:51
Accelerating the next generation of therapeutics to improve the standard of care for the most challenging diseases in cancer, autoimmune and inflammatory disease
July 2025
Nasdaq: ZYME | zymeworks.com
Starting with Patients Driven by Science & Empowered by People
Focusing on challenging, multi-factorial diseases with significant unmet medical needs, including aggressive cancers with historically low survival rates and complex autoimmune and inflammatory disorders that remain difficult to treat
Focused on developing
best-in-class multifunctional therapeutics that hold the potential to optimize patient outcomes
Suite of ADC technologies combines the precision of antibodies with the power of potent proprietary payloads for targeted delivery to cells
Clinically validated proprietary MSAT technology, Azymetric and suite of MSAT technologies enhance therapy precision, efficacy, and adaptability, targeting complex disease mechanisms
Robust leadership team with decades of experience in drug discovery, development, and commercialization
Renowned scientists and researchers in protein engineering, MSATs, and ADC technologies
Global scope, operating across North America, Europe, and Asia
Productive and efficient organization focused on transformative drug discovery with cash resources of approx.
$321.6M1
ADC: antibody-drug conjugate; MSAT: multispecific antibody therapeutic
1. Cash, cash equivalents, and marketable securities as of March 31, 2025 3
Solid Tumor Oncology: Antibody-Drug Conjugates (ADC)
Program Technology Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
ZW191
Topo1i ADC | DAR 8 | Fc WT
ZW220
Topo1i ADC |DAR 4 | Fc Mut
ZW251
Development partners: Jazz Pharmaceuticals and BeOne
Topo1i ADC | DAR 4 | Fc WT
ZD06519 Payload FRα Gynecolog ical Thoracic
ZD06519 Payload NaPi2b Gynecolog ical Thoracic
ZD06519 Payload GPC3 Digestive System
(HCC)
NCT06555744
Solid Tumor Oncology: Multispecific Antibody Therapeutics (MSAT)
Zanidatam ab
Bispecific
Azyme tric HER2 Multiple indications
ZW171
Trivalent TCE | 2+1 Format
Azymetric
Novel anti-CD3
MSLN x CD3
Gynecolog ical
Thoracic
NCT06523803
ZW209
Trispecific TCE | Tri-TCE Costim
ZW239
Trispecific TCE | Tri-TCE Costim
Azyme tric
Novel anti-CD3 Conditional CD28 Azyme tric
Novel anti-CD3
Conditional CD28
DLL3 x CD3 Thoracic
x CD28
CLDN18 .2 Digestive System x CD3 x CD28
Anticipated IND 1H 2026
Autoimmune & Inflammatory Diseases
ZW1528
Dual Cytokine Blocker
Azymetric
Hetero-Fab | YTE
IL4Rα x IL-33
Anticipated IND 2H 2026
ZW1572
Dual Cytokine Blocker
Azymetric
Hetero-Fab | YTE
IL4Rα x IL-31
4
Leading the development of next generation antibody-drug conjugates
Zymelink Hemiasterlin s Auristatin
PreCysion Site- Specific Conjugation
ZW220 s ZW251
nominations
TOPO1i Platform
ZW191
Novel Payload Mechanisms s Targeting Moieties
2010 2012 2014 2016 2018 2020 2022 2024
2026
2027
EFECT
AZYMETRIC
Bi-paratopic
2+1 TCE
Engineering
TriTCE Costim
Novel Targeting Moieties
Currently partnered with:
Engineering
Zanidatamab
FcgRIIb selective
ZW171
RsD day
'5x5' launched
ZW209
ADVANCE
expansion to AIID
s HemeOnc
Azymetric
Clinically validated technology drives development of novel multispecific therapeutics
Ziihera® approved in
2L HER2-positive BTC
Nov 2024
Cytokine Engineering
ZW1528 nomination
BTC: biliary tract cancer; TCE: t cell engager; TOPO1i: topoisomerase 1 inhibitor; 2L: second-line.
5
Disclaimer
Zymeworks Inc. published this content on July 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 08, 2025 at 09:50 UTC.